Docetaxel - Generic Drug Details

What are the generic sources for docetaxel and what is the scope of patent protection?

Docetaxel is the generic ingredient in five branded drugs marketed by Sun Pharm, Accord Hlthcare, Actavis, Alembic, Amneal, Apotex Inc, Dfb Oncology Ltd, Dr Reddys, Eugia Pharma, Gland, Guangdong Sunho, Hengrui Pharma, Heritage, Hikma, Hospira Inc, Ingenus Pharms Llc, Meitheal, Mylan Labs Ltd, Pfizer Labs, Pharmobedient, Sandoz, Shilpa, Teva Pharms Usa, Sanofi Aventis Us, Zhuhai, and Avyxa Holdings, and is included in thirty-one NDAs. There are eight patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Docetaxel has sixty-five patent family members in twenty-seven countries.

There are forty-one drug master file entries for docetaxel. Twenty-three suppliers are listed for this compound.

Summary for docetaxel

International Patents:	65
US Patents:	8
Tradenames:	5
Applicants:	26
NDAs:	31
Drug Master File Entries:	41
Finished Product Suppliers / Packagers:	23
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	2,705
Patent Applications:	8,181
Drug Prices:	Drug price trends for docetaxel
What excipients (inactive ingredients) are in docetaxel?	docetaxel excipients list
DailyMed Link:	docetaxel at DailyMed

See drug prices for docetaxel

Recent Clinical Trials for docetaxel

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Cancer Institute (NCI)	PHASE3
BeyondSpring Pharmaceuticals Inc.	PHASE3
Relmada Therapeutics, Inc.	PHASE3

See all docetaxel clinical trials

Pharmacology for docetaxel

Drug Class	Microtubule Inhibitor
Physiological Effect	Microtubule Inhibition

Anatomical Therapeutic Chemical (ATC) Classes for docetaxel

L01CD	Taxanes
L01C	PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

Paragraph IV (Patent) Challenges for DOCETAXEL

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TAXOTERE	Injection	docetaxel	40 mg/mL, 0.5 mL and 2 mL vials	020449	1	2009-06-30

US Patents and Regulatory Information for docetaxel

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mylan Labs Ltd	DOCETAXEL	docetaxel	INJECTABLE;INJECTION	210848-001	Jul 6, 2018	AP	RX	No	No
Heritage	DOCETAXEL	docetaxel	INJECTABLE;INJECTION	216677-003	Nov 26, 2024	AP	RX	No	No
Amneal	DOCETAXEL	docetaxel	INJECTABLE;INJECTION	209640-002	Jan 19, 2018	AP	RX	No	Yes
Shilpa	DOCETAXEL	docetaxel	INJECTABLE;INJECTION	210327-002	May 16, 2019	AP	RX	No	No

Expired US Patents for docetaxel

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sanofi Aventis Us	TAXOTERE	docetaxel	INJECTABLE;INJECTION	020449-001	May 14, 1996

EU/EMA Drug Approvals for docetaxel

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Accord Healthcare S.L.U.	Docetaxel Accord	docetaxel	EMEA/H/C/002539Breast cancerDocetaxel Accord in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:operable node-positive breast cancer;operable node-negative breast cancer.For patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.Docetaxel Accord in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.Docetaxel Accord monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent.Docetaxel Accord in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2 and who previously have not received chemotherapy for metastatic disease.Docetaxel Accord in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.Non-small-cell lung cancerDocetaxel Accord is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer after failure of prior chemotherapy.Docetaxel Accord in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small-cell lung cancer, in patients who have not previously received chemotherapy for this condition.Prostate cancerDocetaxel Accord in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.Gastric adenocarcinomaDocetaxel Accord in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.Head and neck cancerDocetaxel Accord in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.	Authorised	yes	no	no	2012-05-22
Teva B.V.	Docetaxel Teva	docetaxel	EMEA/H/C/001107Breast cancerDocetaxel Teva in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:operable node-positive breast cancer;operable node-negative breast cancer.For patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.Docetaxel Teva in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.Docetaxel Teva monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy.Previous chemotherapy should have included an anthracycline or an alkylating agent.Docetaxel Teva in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2 and who previously have not received chemotherapy for metastatic disease.Docetaxel Teva in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.Non-small-cell lung cancerDocetaxel Teva is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer after failure of prior chemotherapy.Docetaxel Teva in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small-cell lung cancer, in patients who have not previously received chemotherapy for this condition.Prostate cancerDocetaxel Teva in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.Gastric adenocarcinomaDocetaxel Teva in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.Head and neck cancerDocetaxel Teva in combination with cisplatin and 5 fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.	Withdrawn	yes	no	no	2010-01-26
Sanofi Mature IP	Taxotere	docetaxel	EMEA/H/C/000073Breast cancerTaxotere in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:operable node-positive breast cancer;operable node-negative breast cancer.For patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.Taxotere in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.Taxotere monotherapy is indicated for the treatment of patients with locally advanced ormetastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent.Taxotere in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2 and who previously have not received chemotherapy for metastatic disease.Taxotere in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.Non-small-cell lung cancerTaxotere is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer after failure of prior chemotherapy.Taxotere in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small-cell lung cancer, in patients who have not previously received chemotherapy for this condition.Prostate cancerTaxotere in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.Gastric adenocarcinomaTaxotere in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.Head and neck cancerTaxotere in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.	Authorised	no	no	no	1995-11-27
Fresenius Kabi Deutschland GmbH	Docetaxel Kabi	docetaxel	EMEA/H/C/002325Breast cancerDocetaxel Kabi in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:operable node-positive breast cancer;operable node-negative breast cancer.For patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.Docetaxel Kabi in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.Docetaxel Kabi monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent.Docetaxel Kabi in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2 and who previously have not received chemotherapy for metastatic disease.Docetaxel Kabi in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.Non-small-cell lung cancerDocetaxel Kabi is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer after failure of prior chemotherapy.Docetaxel Kabi in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small-cell lung cancer, in patients who have not previously received chemotherapy for this condition.Prostate cancerDocetaxel Kabi in combination with prednisone or prednisolone is indicated for the treatment of patients with castration-resistant metastatic prostate cancer.Docetaxel Kabi in combination with androgen-deprivation therapy (ADT), with or without prednisone or prednisolone, is indicated for the treatment of patients with metastatic hormone-sensitive prostate cancer.Gastric adenocarcinomaDocetaxel Kabi in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.Head and neck cancerDocetaxel Kabi in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.	Authorised	yes	no	no	2012-05-22

International Patents for docetaxel

Country	Patent Number	Title	Estimated Expiration
China	107427486
China	111714449
China	111728940
China	111728941

Supplementary Protection Certificates for docetaxel

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1667986	92172	Luxembourg		PRODUCT NAME: SOLVAT ACETONIQUE DU CABAZITAXEL, OU DESIGNE SOLVAT ACETONIQUE DU DIMETHOXY DOCETAXEL OU SOLVAT ACETONIQUE DU (2R,3S)-3-TERT-BUTOXYCARBONYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE DE 4-ACETOXY-2A-BENZOYLOXY-5BETA,20-EPOXY-1-HYDROXY-7BETA,10A-DIMETHOXY-9-OXO-TAX-11-ENE-13A-YLE(ACETONATE DU CABAZITAXEL)
1667986	28/2013	Austria		PRODUCT NAME: DIMETHOXYDOCETAXEL-ACETONSOLVAT (CABAZITAXEL-ACETONSOLVAT); REGISTRATION NO/DATE: EU/1/11/676/001 20110317
0253738	C960002	Netherlands		PRODUCT NAME: DOCETAXEL, DESGEWENST IN DE VORM VAN EEN TRIHYDRAAT; REGISTRATION NO/DATE: EU/1/95/002/001 - EU/1/95/002/002 19951127

Docetaxel Market Dynamics and Financial Trajectory (Global and US Revenue Risk, Competition, and Exclusivity/Pricing Drivers)

Last updated: July 23, 2026

Docetaxel remains a high-volume oncology cytotoxic where market value is driven by (1) pricing compression versus loss of branded share, (2) shift toward combination regimens, and (3) stable late-line demand. Financial trajectory is increasingly constrained by generic penetration in the US and EU, offset only partially by ongoing physician preference for established dosing brands and by periodic rebounds from supply stability and pack-size pricing.

---

Docetaxel Market Size, Demand Drivers, and Where Revenue Comes From

Docetaxel is used across multiple tumor types, and demand is sustained by broad guideline inclusion in metastatic and adjuvant settings.

Key demand engines

• Breast cancer: metastatic breast cancer in combination regimens; continued use in protocol-based care.
• Non-small cell lung cancer (NSCLC): chemotherapy backbone in multiple lines and combinations.
• Prostate cancer: commonly integrated in metastatic hormone-sensitive and castration-resistant treatment sequences (noting that many modern pathways now prioritize newer agents in specific subpopulations).
• Gastric and other solid tumors: included in multi-drug regimens in certain geographies and protocol frameworks.

Revenue mix implication

• The market is less dependent on one single indication and more exposed to overall oncology chemotherapy trends, combination intensity, and payer-driven substitution to lower-cost multisource products.

---

Who Sells Docetaxel and How Has Competition Erodled Pricing?

Docetaxel is a mature, off-patent oncology agent in most major markets. That structure produces a predictable pricing curve: branded unit pricing declines first, then gross-to-net pressure rises as generics expand.

Typical competitive pattern

• Early-stage: originator or branded lead with limited competitors.
• Mid-stage: multisource entry triggers price competition, with tendering and hospital formulary decisions tightening.
• Late-stage: most surviving distributors compete on packaging, supply reliability, and contract pricing rather than clinical differentiation.

What materially changes pricing

• National tender cycles and hospital contracting.
• Bundle contracting with infusion services.
• Specialty distribution and rebate terms.
• Supply constraints (if they occur) that temporarily raise acquisition prices.

---

What Is the US Docetaxel Market Share Structure and Expected Revenue Erosion Pace?

In the US, docetaxel revenue has faced sustained gross margin compression due to multisource availability and payer formularies. The trajectory typically shows:

• rapid decline from branded share to multisource share,
• then slower unit-value decline as generics compete on acquisition price and logistics.

Commercial outcome

• Revenue growth is unlikely without new clinical differentiation or a major treatment paradigm shift.
• Value tends to track volume plus small pricing changes from contract renegotiations and supply dynamics.

---

How Does Docetaxel Compare With Other Taxanes (Paclitaxel, Cabazitaxel) on Competitive Economics?

Taxane class competition drives substitution pressure even when clinical positioning differs.

Economic comparison lens

• Paclitaxel: often faces intense biosupply and generic competition as well, but in many settings has a strong protocol footprint across breast and other cancers.
• Cabazitaxel: higher priced and more differentiated, but narrower eligibility and line-of-therapy constraints limit its ability to fully substitute docetaxel volume.

Docetaxel implication

• Docetaxel often functions as a cost-effective standard in regimens where clinicians maintain taxane-based backbone treatment.
• As newer targeted and immunotherapy regimens expand, taxane chemotherapy share can shrink in some patient segments, shifting docetaxel usage to specific lines or combinations.

---

What Patents Protect Docetaxel Products Today, and How Much IP Still Matters?

Docetaxel is long since off foundational patent protection in most jurisdictions. Practical residual IP typically relates to:

• formulation improvements (vehicles, excipient systems, particle control),
• manufacturing process claims,
• method-of-use claims in narrower regimens (when still asserted),
• combination products (less common for docetaxel as a standalone generic backbone).

Commercial reality

• For most payer and procurement decisions, residual patents do not block multisource generic supply at scale.
• Any remaining exclusivity tends to be product-specific (a particular formulation or labeled regimen) and often expires or is avoided through approved labeling changes and manufacturing routes.

---

What Formulations Are Protected by Patents for Docetaxel (and Do Those Affect Pricing)?

Docetaxel is typically supplied as an intravenous infusion requiring a vehicle system. In competitive markets, formulation differentiation can matter for:

• infusion-related tolerability and supportive care requirements,
• compatibility with infusion workflows,
• stability and handling during pharmacy compounding or hospital preparation.

Pricing impact

• Even when a formulation is claimed, multisource penetration often proceeds via design-around strategies and commercial interchangeability once labeled as therapeutically equivalent.
• If a formulation has a distinct handling advantage, it can temporarily protect unit share through procurement preference.

---

When Does Docetaxel Lose Exclusivity for Specific Products, and What Are the Generic Entry Risks?

Because docetaxel is mature and largely generic, “exclusivity loss” is usually not a single corporate event. Instead, it manifests as:

• end of remaining branded product exclusivity for specific packaging or strength presentations,
• depletion of regulatory exclusivities tied to specific NDA approvals,
• patent expirations that no longer block ANDA approvals.

Generic entry risk profile

• Low for system-wide docetaxel bulk supply.
• Higher for particular branded presentations if they had formulation or process protection that delayed ANDA readiness.

---

What Is the Orange Book Status of Docetaxel Products?

Docetaxel is widely represented in the FDA’s Orange Book with multiple approved ANDAs. The market structure typically shows:

• many therapeutically equivalent listings,
• older branded entries with extensive substitution history,
• product-level differences that do not prevent large-scale generic coverage.

Practical meaning for market participants

• Any attempt to block generic substitution would require strong, actively litigated, product-specific claims.
• From a forecasting standpoint, Orange Book density implies limited ability to sustain premium pricing through IP alone.

---

What Paragraph IV Challenges and Patent Litigation Have Affected Docetaxel Generic Supply?

For mature cytotoxics like docetaxel, litigation has historically been used to delay ANDA launches. In the current stage of the lifecycle:

• the biggest earnings impacts typically occurred when the first wave of ANDAs broke branded dominance,
• subsequent challenges tended to be smaller in commercial scope, tied to remaining product-specific claims.

Litigation-driven effects

• Temporary delays that can raise near-term sales for the last branded supplier or a protected formulation.
• Settlement-driven launch dates that compress remaining time windows for competitors.

---

How Many Patents Cover Docetaxel Products in Key Markets, and Which Types Matter Most?

Patent coverage in practice is multi-layered:

• composition and derivatives at early life stage (largely expired),
• formulation vehicle excipient systems,
• manufacturing method claims,
• narrow method-of-use claims (if any remain asserted).

Most economically relevant

• formulation/process claims that can delay “drop-in” manufacturing for a generic.
• any remaining method claims that affect labeling and substitution.

---

Biosimilar Risk: Does Docetaxel Have Any Biological Follow-On Risk?

Docetaxel is a small-molecule drug, so biosimilar risk is not applicable.

---

FDA Regulatory Pathways for Docetaxel: How Do ANDAs Influence Supply and Pricing?

Docetaxel’s market access is dominated by ANDAs using therapeutically equivalent standards.

Regulatory implications

• Once an ANDA is approved, supply can scale quickly.
• Pricing pressure accelerates as multiple manufacturers compete for contracting slots.
• Product comparability is usually sufficient for substitution once interchangeability is accepted by payers and formularies.

---

How Do Manufacturing and Supply Chain Constraints Affect Docetaxel Revenue?

Even with generic competition, oncology injectables can experience:

• batch release variability,
• raw material availability constraints,
• manufacturing capacity limitations.

Revenue impact

• Temporary price and allocation effects can lift revenue and gross margin in constrained periods.
• Over time, increased supply returns the market to contract price levels.

---

Commercial Trajectory: What Does the Financial Pattern Look Like Over the Lifecycle?

A typical docetaxel financial trajectory in mature markets follows:

1. Branded peak or plateau in early adoption,
2. step-down after initial generic entries,
3. sustained revenue decline with gradual stabilization at a lower unit price floor driven by contracting,
4. episodic upticks from supply tightening rather than structural price growth.

Key business interpretation

• Long-term growth is primarily volume-driven through continued regimen inclusion, not value growth.
• Profit pools shift to low-cost manufacturing scale and to supply reliability.

---

Which Regions Offer the Best Docetaxel Value Pool, and Where Is Growth Most Constrained?

Higher value regions (relative)

• Markets with slower generic uptake, tender friction, or reimbursement structures that slow substitution.
• Regions with persistent branded usage in protocol-driven chemotherapy workflows.

Lower value regions (relative)

• Markets with rapid multicountry tendering and dense generic listings.
• Countries with aggressive price caps for established cytotoxics.

---

Docetaxel Revenue Sensitivity: How Exposed Is the Market to Reimbursement Changes?

Docetaxel is reimbursement-sensitive because:

• it is widely substitutable to generics,
• it sits in budget-sensitive oncology chemo lines,
• chemotherapy formularies can shift quickly with new entrants and pathway updates.

Sensitivity profile

• High exposure to procurement-driven unit price and contract renegotiation cycles.
• Lower exposure to clinical reclassification (since it is entrenched in chemo protocols).

---

Key Risks to the Docetaxel Financial Trajectory (What Could Break the Downward Price Trend)?

The most plausible short-to-mid-term disruptors:

• supply interruptions that reduce availability and raise contract prices,
• limited manufacturing capacity among certain suppliers leading to allocation,
• temporary regulatory actions that change which listings are available,
• localized tender lock-in for certain label-equivalent products based on handling or logistics.

Lower probability disruptors

• major clinical breakthroughs (unlikely for a mature small molecule without a new formulation breakthrough),
• broad guideline reversal in favor of taxane regimens across new populations (depends on evolving standard-of-care).

---

Key Takeaways

• Docetaxel’s market is mature and driven primarily by volume stability and procurement pricing cycles rather than IP-led differentiation.
• Competitive dynamics are dominated by multisource ANDA availability, yielding sustained gross-to-net pressure and structurally lower unit value.
• Financial trajectory is best modeled as volume plus contract-price movements, with revenue spikes mainly linked to supply constraints rather than durable price expansion.
• Litigation and exclusivity impacts are historically important for prior waves of generic entry but offer limited current protection across the broader docetaxel landscape.

---

FAQs

1) Why does docetaxel continue to have demand despite generic penetration?
Because it remains embedded in chemotherapy regimens with stable clinical utility and broad treatment workflows where contract pricing and availability drive selection.

2) What procurement variables influence which docetaxel generic wins formulary coverage?
Tender timing, pack size pricing, allocation reliability, distribution terms, and pharmacy handling compatibility.

3) Can docetaxel revenue rebound without patent protection?
Yes, short-term rebounds can occur from supply constraints or contract repricing, but they typically do not reset the long-run price floor.

4) How does the growth of immuno-oncology and targeted therapies affect docetaxel market volume?
It can reduce chemo usage in some first-line segments, shifting docetaxel demand to specific lines and combination protocols.

5) Is there any formulation strategy that meaningfully protects docetaxel pricing?
Formulation or process differentiation can protect a product presentation temporarily, but broad interchangeability and therapeutically equivalent approvals usually cap long-term pricing durability.

---

References

1. FDA. “Drugs@FDA: FDA Approved Drug Products.” Accessed July 23, 2026.
2. FDA. “Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.” Accessed July 23, 2026.
3. FDA. “ANDA Guidance Documents and Regulatory Pathway Information.” Accessed July 23, 2026.